Abstract: An ultrasonic transducer that operates in flexure mode provides a highly efficient and compact sonophoresis device. Such a device is particularly useful for efficiently enhancing permeation of a substance through a membrane, such as dermal and mucosal membranes for purposes of transdermal/transmucosal drug delivery and/or body fluid monitoring.
Abstract: Thiazolo-, oxazolo- and selenazolo[4,5-c]quinolin-4-amines and analogs thereof are described including methods of manufacture and the use of novel intermediates. The compounds are immunomodulators and induce cytokine biosynthesis, including interferon and/or tumor biosynthesis, necrosis factor, and inhibit the T-helper-type 2 immune response. The compounds are further useful in the treatment of viral and neoplastic diseases.
Type:
Grant
Filed:
June 14, 2000
Date of Patent:
November 27, 2001
Assignee:
3M Innovative Properties Company
Inventors:
John F. Gerster, Kyle J. Lindstrom, Gregory J. Marszalek, Bryon A. Merrill, John W. Mickelson, Michael J. Rice
Abstract: A medicinal aerosol steroid solution formulation product with enhanced chemical stability. The steroid is a 20-ketosteroid having an OH group at the C-17 or C-21 position and the aerosol container has a non-metal interior surface which has been found to reduce chemical degradation of such steroids.
Type:
Grant
Filed:
June 13, 2000
Date of Patent:
November 13, 2001
Assignee:
3M Innovative Properties Company
Inventors:
Zheng Z. Wu, Nayna Govind, Peter R. Johnson
Abstract: Transdermal drug delivery compositions comprising pressure sensitive adhesive microspheres that contain a softening agent and/or a drug. Typically the microspheres contain at least 10 wt-% of a softening agent. The drug and/or softening agent can be incorporated into the microspheres during or after their formation.
Type:
Grant
Filed:
May 1, 1998
Date of Patent:
November 6, 2001
Assignee:
3M Innovative Properties Company
Inventors:
Adam S. Cantor, Hye-ok Choi, Joaquin Delgado, Chan U. Ko, Thu-Van Tran
Abstract: A pharmaceutical aerosol formulation suitable for oral and/or nasal inhalation including an anti-inflammatory steroid of the formula
in which:
R1 is 1-butyl, 2-butyl, cyclohexyl or phenyl and
R2 is acetyl or isobutanoyl, in particular ciclesonide. The formulations also include hydrofluorocarbon propellants such as HFC 134a and/or 227, and cosolvent such as ethanol in an amount sufficient to solubilize the ciclesonide or related steroid (and various optional ingredients, such as surfactant). The formulations exhibit very desirable physical and chemical stability, as well as excellent delivery characteristics.
Type:
Grant
Filed:
November 15, 1999
Date of Patent:
July 24, 2001
Assignee:
3M Innovative Properties Company
Inventors:
Martin J. Oliver, Kanu M. Fatania, John S. Scott, Helgert Muller
Abstract: Immune response modifier (IRM) compounds—imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, thiazolo- and oxazolo-quinolinamines and pyridinamines, imidazonaphthyridine and tetrahydroimidazonaphthyridine amines—are useful for the treatment of conditions at and below the mucosal surfaces by administering a therapeutically effective amount of such compounds to the mucosal surface. Novel pharmaceutical formulations are provided. In one embodiment, the pharmaceutical formulations are advantageous for treatment of cervical conditions such as cervical dysplasias including cervical intraepithelial neoplasias.
Type:
Grant
Filed:
January 7, 2000
Date of Patent:
June 12, 2001
Assignee:
3M Innovative Properties Company
Inventors:
Raymond D. Skwierczynski, Kenneth R. Phares, Richard L. Miller, Zheng Jane Li, Michael J. Jozwiakowski, Terri F. Busch
Abstract: Immune response modifier compounds—imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2-bridged imidazoquinoline amines—are useful for the treatment of TH2 mediated diseases by administering a therapeutically effective amount of such compounds in order to inhibit TH2 immune response, suppress IL-4/IL-5 cytokine induction and eosinophilia, as well as enhance TH1 immune response.
Type:
Grant
Filed:
March 20, 2000
Date of Patent:
March 13, 2001
Assignee:
3M Innovative Properties Company
Inventors:
Mark A. Tomai, David M. Hammerbeck, Karl F. Swingle
Abstract: The present invention provides a pressure sensitive skin adhesive comprising:
(a) a copolymer of one or more alkyl(meth)acrylates containing 4 to 12 carbon atoms in the alkyl group and one or more hydrophilic monomers;
(b) a mixture of penetration enhancers comprising:
(i) an alkyl ester of an aliphatic monocarboxylic acid containing 1 to 5 carbon atoms in the alkyl group
(ii) an alkyl pyrrolidone and
(iii) an alkane polyol
(c) a therapeutically effective amount of diclofenac or a pharmaceutically acceptable salt thereof.
Further provided is a transdermal drug delivery device containing the pressure sensitive skin adhesive.
Type:
Grant
Filed:
March 25, 1999
Date of Patent:
February 27, 2001
Assignee:
3M Innovative Properties Company
Inventors:
Jochem J. Effing, Anja N. Becker, Carsten Coors
Abstract: Imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds induce the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compounds exhibit antiviral and antitumor properties. Methods of preparing the compounds and intermediates useful in the preparation of the compounds are also disclosed.
Type:
Grant
Filed:
December 11, 1998
Date of Patent:
February 27, 2001
Assignee:
3M Innovative Properties Company
Inventors:
John F. Gerster, Kyle J. Lindstrom, Stephen L. Crooks, Philip D. Heppner, Gregory J. Marszalek, Peter V. Maye, Bryon A. Merrill, John W. Mickelson, Michael J. Rice
Abstract: A process for preparing 1H-imidazo[4,5-c]quinolin-4-amines is disclosed. The process involves reacting a 6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline with triphenylphosphine and hydrolyzing the product thereof.
Abstract: The present invention provides a transdermal drug delivery composition comprising:(a) a copolymer of one or more (meth)acrylate monomers being selected from the group consisting of alkyl acrylates containing 4 to 12 carbon atoms in the alkyl group and alkyl methacrylates containing 4 to 12 carbon atoms in the alkyl group and one or more hydrophilic monomers being copolymerizable with said (meth)acrylate monomers, and(b) a therapeutically effective amount of lerisetron. The transdermal drug delivery composition is used to make a transdermal drug delivery device for the delivery of lerisetron.
Abstract: A transdermal delivery device including an adhesive layer that contains a therapeutically effective amount of testosterone and a delivery enhancing adjuvant comprising a terpene.
Type:
Grant
Filed:
February 27, 1998
Date of Patent:
October 17, 2000
Assignee:
3M Innovative Properties Company
Inventors:
John C. Hedenstrom, Michael L. Husberg, Shari L. Wilking, Matthew T. Scholz
Abstract: Methods, compounds, and medicinal formulations utilizing biocompatible polymers for delivery of a drug, particularly for solubilizing, stabilizing and/or providing sustained release of drug from topical, implantable, and inhalation systems. Many of the methods, compounds, and medicinal formulations are particularly suitable for oral and/or nasal inhalation and use polymers of the formula --[X--R.sup.1 --C(O)]-- wherein each R.sup.1 is an independently selected organic group that links the --X-- group to the carbonyl group, and each X is independently oxygen, sulfur, or catenary nitrogen.
Type:
Grant
Filed:
February 7, 1997
Date of Patent:
October 3, 2000
Assignee:
3M Innovative Properties Company
Inventors:
James S. Stefely, David W. Schultz, Luke E. Schallinger, Craig A. Perman, Chester L. Leach, Daniel C. Duan
Abstract: Bishydroxyureas are provided that inhibit the enzyme 5-lipoxygenase. These compounds have the formula I ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, A and M are defined herein. Also disclosed are pharmaceutical compositions containing such compounds and methods of inhibiting the enzyme 5-lipoxygenase using such compounds.
Abstract: A pharmaceutical aerosol formulation suitable for oral and/or nasal inhalation including an anti-inflammatory steroid of the formula ##STR1## in which: R.sub.1 is 1-butyl, 2-butyl, cyclohexyl or phenyl andR.sub.2 is acetyl or isobutanoyl, in particular ciclesonide. The formulations also include hydrofluorocarbon propellants such as HFC 134a and/or 227, and cosolvent such as ethanol in an amount sufficient to solubilize the ciclesonide or related steroid (and various optional ingredients, such as surfactant). The formulations exhibit very desirable physical and chemical stability, as well as excellent delivery characteristics.
Abstract: Actuator system is used to dispense a defined volume of a formulation from a pressurized vial. The system houses the vial in a receptacle of a base section that also includes a dispensing section (e.g., a funnel) through which the formulation is sprayed. The system includes a sleeve that fits over at least the vial and that can be pumped by the user to controllably spray the formulation from the vial onto the host animal. For instance, in a preferred mode of operation, the user places the system onto the host at the desired treatment site and then pushes or pulls down on the sleeve. This actuates a valve mechanism on the vial to spray an amount of the formulation through the dispensing section onto the host.
Type:
Grant
Filed:
August 20, 1998
Date of Patent:
September 5, 2000
Assignee:
3M Innovative Properties Company
Inventors:
Cathleen M. Arsenault, James A. Wilson, David J. Wirtanen
Abstract: Thiazolo-, oxazolo- and selenazolo[4,5-c]quinolin-4-amines and analogs thereof are described including methods of manufacture and the use of novel intermediates. The compounds are immunomodulators and induce cytokine biosynthesis, including interferon and/or tumor biosynthesis, necrosis factor, and inhibit the T-helper-type 2 immune response. The compounds are further useful in the treatment of viral and neoplastic diseases.
Type:
Grant
Filed:
July 27, 1999
Date of Patent:
August 29, 2000
Assignee:
3M Innovative Properties Company
Inventors:
John F. Gerster, Kyle J. Lindstrom, Gregory J. Marszalek, Bryon A. Merrill, John W. Mickelson, Michael J. Rice
Abstract: Optically pure S(+) flurbiprofen, which is substantially free of the R(-) enantiomer, is a potent analgesic for relieving pain and inflammation in humans and animals. A method and composition is disclosed utilizing the optically pure S(+) enantiomer of flurbiprofen for treating pain and inflammation.
Abstract: An immunogen/vaccine adjuvant composition containing an immunogen in an amount effective to stimulate an immune response and as a vaccine adjuvant a 1H-imidazo[4,5-c]quinolin-4-amine in an amount effective to increase the immune response to the immunogen.
Type:
Grant
Filed:
March 24, 1994
Date of Patent:
July 4, 2000
Assignee:
3M Innovative Properties Company
Inventors:
Richard L. Miller, Mark A. Tomai, David I. Bernstein, Christopher J. Harrison
Abstract: A pharmaceutical suspension formulation suitable for aerosol administration having from 0.0025 to 0.1% w/w of micronized Formoterol, or an acid addition salt thereof, from 0.1 to 5.0% w/w ethanol, HFA 134a, HFA 227 or a mixture of HFA 227 and HFA 134a, and optionally a surfactant other than a monoacetylated or diacetylated monoglyceride, the formulation being further characterized in that it exhibits substantially no growth in particle size or change in crystal morphology of the drug over a prolonged period, is substantially and readily redispersible, and upon redispersion does not flocculate so quickly as to prevent reproducible dosing of the drug.
Type:
Grant
Filed:
June 2, 1998
Date of Patent:
April 25, 2000
Assignee:
3M Innovative Properties Company
Inventors:
Martin J. Oliver, Simon G. Paling, Philip A. Jinks, Sukhbinder K. Jaiswal